Skip to main content

Milnacipran Садржај Osobine Reference Literatura Spoljašnje veze Мени за навигацијуMonografija92623-85-3WHO65833DB0489659245CHEMBL25292316869117169589421693266916830129168146901675836730059018923122123696089421348167625341730085923506481„DrugBank 3.0: a comprehensive resource for omics research on drugs”30137092105968210.1093/nar/gkq1126уреди„DrugBank: a knowledgebase for drugs, drug actions and drug targets”22388891804841210.1093/nar/gkm958уреди„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”10.1021/jp980230o„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”1174957310.1021/ci000392tуреди„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”1102028610.1021/jm000942eуредиGoodman & Gilman's The Pharmacological Basis of Therapeutics10.1036/0071422803Foye's Principles of Medicinal ChemistryMilnacipranVikimedijinoj ostaviMilnacipranу

Инхибитори преузимања норепинефринаСелективни инхибитори преузимања серотонинаАцетамидиАмини


organsko jedinjenjeatomaugljenikamolekulsku masuDa










(function()var node=document.getElementById("mw-dismissablenotice-anonplace");if(node)node.outerHTML="u003Cdiv class="mw-dismissable-notice"u003Eu003Cdiv class="mw-dismissable-notice-close"u003E[u003Ca tabindex="0" role="button"u003Eсакријu003C/au003E]u003C/divu003Eu003Cdiv class="mw-dismissable-notice-body"u003Eu003Cdiv id="localNotice" lang="sr" dir="ltr"u003Eu003Cdiv style="position:relative; overflow:hidden; background-color:#5E9DC8; text-align:center; color:white; font-size:1.25em; font-weight:bold; line-height:1.5em; margin-top: 5px;"u003Eu003Cuu003Eu003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%A2%D0%B0%D0%BA%D0%BC%D0%B8%D1%87%D0%B5%D1%9A%D0%B5_%D1%83_%D0%BF%D0%B8%D1%81%D0%B0%D1%9A%D1%83_%D1%87%D0%BB%D0%B0%D0%BD%D0%B0%D0%BA%D0%B0/%D0%A6%D0%95%D0%95_%D0%BF%D1%80%D0%BE%D0%BB%D0%B5%D1%9B%D0%B5_2019" title="Википедија:Такмичење у писању чланака/ЦЕЕ пролеће 2019"u003Eu003Cspan style="color:white"u003EТакмичите се у писању чланака о Средњој и Источној Европи од 21. марта до 31. маја!u003C/spanu003Eu003C/au003Eu003C/uu003Eu003C/divu003Enu003Cdiv style="position:relative; overflow:hidden; background-color:#5E9DC8; text-align:center; color:white; font-size:1.25em; font-weight:bold; line-height:1.5em; margin-top: 5px;"u003EУ току је гласање о u003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%93%D0%BB%D0%B0%D1%81%D0%B0%D1%9A%D0%B5/%D0%9E%D0%BC%D0%BE%D0%B3%D1%83%D1%9B%D0%B0%D0%B2%D0%B0%D1%9A%D0%B5_%D0%B4%D0%B5%D0%BB%D0%B8%D0%BC%D0%B8%D1%87%D0%BD%D0%B8%D1%85_%D0%B1%D0%BB%D0%BE%D0%BA%D0%B0%D0%B4%D0%B0" title="Википедија:Гласање/Омогућавање делимичних блокада"u003Eu003Cspan style="color:white"u003Eu003Cuu003Eомогућавању делимичних блокадаu003C/uu003Eu003C/spanu003Eu003C/au003E и u003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%93%D0%BB%D0%B0%D1%81%D0%B0%D1%9A%D0%B5/%D0%9E%D0%BC%D0%BE%D0%B3%D1%83%D1%9B%D0%B0%D0%B2%D0%B0%D1%9A%D0%B5_%D0%92%D0%B8%D0%B7%D1%83%D0%B5%D0%BB%D0%BD%D0%BE%D0%B3_%D1%83%D1%80%D0%B5%D1%92%D0%B8%D0%B2%D0%B0%D1%87%D0%B0_%D1%83_%D0%BF%D1%80%D0%BE%D1%81%D1%82%D0%BE%D1%80%D1%83_%D0%BD%D0%B0%D1%86%D1%80%D1%82%D0%B0" title="Википедија:Гласање/Омогућавање Визуелног уређивача у простору нацрта"u003Eu003Cspan style="color:white"u003Eu003Cuu003EВизуелног уређивача у простору нацртаu003C/uu003Eu003C/spanu003Eu003C/au003E!u003C/divu003Enu003Cdiv style="position:relative; overflow:hidden; background-color:#5E9DC8; text-align:center; color:white; font-size:1.25em; font-weight:bold; line-height:1.5em; margin-top: 5px;"u003Eu003Cuu003Eu003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%93%D0%BB%D0%B0%D1%81%D0%B0%D1%9A%D0%B5/%D0%9F%D1%80%D0%B5%D0%B4%D0%BB%D0%BE%D0%B3/%D0%94%D0%BE%D0%BF%D1%83%D0%BD%D0%B0_%D0%BF%D1%80%D0%B0%D0%B2%D0%B8%D0%BB%D0%B0_%D0%BE_%D0%B8%D0%B7%D0%B0%D0%B1%D1%80%D0%B0%D0%BD%D0%B8%D0%BC_%D1%81%D0%BB%D0%B8%D0%BA%D0%B0%D0%BC%D0%B0" title="Википедија:Гласање/Предлог/Допуна правила о изабраним сликама"u003Eu003Cspan style="color:white"u003EУ току је расправа о допуни правила везаних за изабране слике!u003C/spanu003Eu003C/au003Eu003C/uu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003E";());




Milnacipran




Из Википедије, слободне енциклопедије






Иди на навигацију
Иди на претрагу































Milnacipran
Milnacipran Enantiomers Structural Formulae V2.svg
Milnacipran3Dan.gif
Klinički podaci
Prodajno imeDalcipran, Ixel, Savella, Toledomin
Drugs.comMonografija
Način primeneOralno

Farmakokinetički podaci
Poluvreme eliminacije6-8 sati
IzlučivanjeUrinom (50%- 60%, 24% kao l-milnacipran i 31% kao d-milnacipran)

Identifikatori
CAS broj
92623-85-3 ДаY
ATC kod
N06AX17 (WHO)
PubChemCID 65833
DrugBank
DB04896 ДаY
ChemSpider
59245 ДаY
ChEMBL
CHEMBL252923 ДаY
Hemijski podaci
Formula
C15H22N2O
Molarna masa246,348



Fizički podaci
Tačka topljenja
179 °C (354 °F)

Milnacipran je organsko jedinjenje, koje sadrži 15 atoma ugljenika i ima molekulsku masu od 246,348 Da.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]




Садржај





  • 1 Osobine


  • 2 Reference


  • 3 Literatura


  • 4 Spoljašnje veze




Osobine
















OsobinaVrednost
Broj akceptora vodonika2
Broj donora vodonika1
Broj rotacionih veza5

Particioni koeficijent[16] (ALogP)
1,3

Rastvorljivost[17] (logS, log(mol/L))
-3,0

Polarna površina[18] (PSA, Å2)
46,3


Reference




  1. ^ Leo RJ, Brooks VL: Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42. PMID 16869117


  2. ^ Sato S, Yamakawa Y, Terashima Y, Ohta H, Asada T: Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study. Psychiatry Clin Neurosci. 2006 Oct;60(5):584-9. PMID 16958942


  3. ^ Simon LS: Is milnacipran effective in treating pain in patients with fibromyalgia? Nat Clin Pract Rheumatol. 2006 Mar;2(3):126-7. PMID 16932669


  4. ^ Soya A, Terao T, Nakajima M, Kojima H, Okamoto T, Inoue Y, Iwakawa M, Shinkai K, Yoshimura R, Ueta Y, Nakamura J: Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers. Psychopharmacology (Berl). 2006 Sep;187(4):526-7. Epub 2006 Jul 8. PMID 16830129


  5. ^ King T, Rao S, Vanderah T, Chen Q, Vardanyan A, Porreca F: Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran. J Pain. 2006 Jul;7(7):513-20. PMID 16814690


  6. ^ Moojen VK, Martins MR, Reinke A, Feier G, Agostinho FR, Cechin EM, Quevedo J: Effects of milnacipran in animal models of anxiety and memory. Neurochem Res. 2006 Apr;31(4):571-7. Epub 2006 May 9. PMID 16758367


  7. ^ Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9. PMID 3005901


  8. ^ Briley M, Prost JF, Moret C: Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:9-14. PMID 8923122


  9. ^ Puozzo C, Panconi E, Deprez D: Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S25-35. PMID 12369608


  10. ^ Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R: Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand. 1997 Dec;96(6):497-504. PMID 9421348


  11. ^ Papakostas GI, Fava M: A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 Jan;17(1):32-6. Epub 2006 Jun 8. PMID 16762534


  12. ^ Kako Y, Niwa Y, Toyomaki A, Yamanaka H, Kitagawa N, Denda K, Koyama T: A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):772-5. Epub 2007 Jan 12. PMID 17300859


  13. ^ Bernstein CD, Albrecht KL, Marcus DA: Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opin Pharmacother. 2013 Mar 19. PMID 23506481


  14. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126.  уреди


  15. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958.  уреди


  16. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 


  17. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди


  18. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди



Literatura


.mw-parser-output .refbeginfont-size:90%;margin-bottom:0.5em.mw-parser-output .refbegin-hanging-indents>ullist-style-type:none;margin-left:0.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>ddmargin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none.mw-parser-output .refbegin-100font-size:100%


  • Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803. 


  • Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799. 



Spoljašnje veze




  • Milnacipran


Star of life.svgMolimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).










Преузето из „https://sr.wikipedia.org/w/index.php?title=Milnacipran&oldid=19473973”










Мени за навигацију



























(window.RLQ=window.RLQ||[]).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.724","walltime":"0.953","ppvisitednodes":"value":4182,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":135224,"limit":2097152,"templateargumentsize":"value":4218,"limit":2097152,"expansiondepth":"value":17,"limit":40,"expensivefunctioncount":"value":0,"limit":500,"unstrip-depth":"value":0,"limit":20,"unstrip-size":"value":18552,"limit":5000000,"entityaccesscount":"value":1,"limit":400,"timingprofile":["100.00% 776.160 1 -total"," 44.96% 348.955 4 Шаблон:Infobox"," 41.22% 319.970 1 Шаблон:Drugbox-lat"," 20.53% 159.314 1 Шаблон:Commonscat-lat"," 19.35% 150.211 1 Шаблон:Reflist"," 14.04% 108.964 4 Шаблон:Cite_pmid"," 13.53% 105.007 5 Шаблон:Cite_journal"," 7.08% 54.919 1 Шаблон:Cite_pmid/21059682"," 4.90% 38.059 1 Шаблон:Infobox_drug-lat/chemical_formula"," 4.05% 31.459 1 Шаблон:Convert-lat"],"scribunto":"limitreport-timeusage":"value":"0.274","limit":"10.000","limitreport-memusage":"value":6788086,"limit":52428800,"cachereport":"origin":"mw1264","timestamp":"20190511070153","ttl":2592000,"transientcontent":false););"@context":"https://schema.org","@type":"Article","name":"Milnacipran","url":"https://sr.wikipedia.org/wiki/Milnacipran","sameAs":"http://www.wikidata.org/entity/Q421058","mainEntity":"http://www.wikidata.org/entity/Q421058","author":"@type":"Organization","name":"u0421u0430u0440u0430u0434u043du0438u0446u0438 u043fu0440u043eu0458u0435u043au0430u0442u0430 u0412u0438u043au0438u043cu0435u0434u0438u0458u0435","publisher":"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png","datePublished":"2013-12-15T06:36:34Z","dateModified":"2018-03-21T10:02:38Z","image":"https://upload.wikimedia.org/wikipedia/commons/6/69/Milnacipran3Dan.gif"(window.RLQ=window.RLQ||[]).push(function()mw.config.set("wgBackendResponseTime":140,"wgHostname":"mw1249"););

Popular posts from this blog

Sahara Skak | Bilen | Luke uk diar | NawigatsjuunCommonskategorii: SaharaWikivoyage raisfeerer: Sahara26° N, 13° O

The fall designs the understood secretary. Looking glass Science Shock Discovery Hot Everybody Loves Raymond Smile 곳 서비스 성실하다 Defas Kaloolon Definition: To combine or impregnate with sulphur or any of its compounds as to sulphurize caoutchouc in vulcanizing Flame colored Reason Useful Thin Help 갖다 유명하다 낙엽 장례식 Country Iron Definition: A fencer a gladiator one who exhibits his skill in the use of the sword Definition: The American black throated bunting Spiza Americana Nostalgic Needy Method to my madness 시키다 평가되다 전부 소설가 우아하다 Argument Tin Feeling Representative Gym Music Gaur Chicken 일쑤 코치 편 학생증 The harbor values the sugar. Vasagle Yammoe Enstatite Definition: Capable of being limited Road Neighborly Five Refer Built Kangaroo 비비다 Degree Release Bargain Horse 하루 형님 유교 석 동부 괴롭히다 경제력

19. јануар Садржај Догађаји Рођења Смрти Празници и дани сећања Види још Референце Мени за навигацијуу